Reshma Kewalramani
CEO & President at Vertex Pharmaceuticals; Director at Ginkgo Bioworks Holdings. Based in Boston, Massachusetts.
- Rank
- 2739th of 14,644
- Companies held
- 2
- Largest holding
- VRTX, 99.9% of total
- Latest SEC filing
- Nov 6, 2026
What the $45.1M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals VRTX Common Stock | Directly | 86,471 | $520.66 | $45.0M | 99.9% | Form 4, Nov 6, 2026 |
| Ginkgo Bioworks Holdings DNA Class A Common Stock | Directly | 4,650 split-adjusted | $8.20 | $38K | 0.1% | Form 4, Jun 12, 2024 |
Share counts are the amounts Reshma Kewalramani reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | Sold | VRTX | 11,866 | $531.53 | $6.3M | View |
| Feb 27, 2026 | Sold | VRTX | 3,278 | $488.27 | $1.6M | View |
| Feb 27, 2026 | Sold | VRTX | 2,510 | $487.13 | $1.2M | View |
| Feb 27, 2026 | Sold | VRTX | 240 | $482.84 | $116K | View |
| Feb 27, 2026 | Sold | VRTX | 120 | $481.50 | $58K | View |
| Feb 27, 2026 | Sold | VRTX | 400 | $479.75 | $192K | View |
| Feb 27, 2026 | Sold | VRTX | 460 | $489.32 | $225K | View |
| Feb 27, 2026 | Sold | VRTX | 1,725 | $496.95 | $857K | View |
| Feb 27, 2026 | Sold | VRTX | 5,995 | $496.16 | $3.0M | View |
| Feb 27, 2026 | Sold | VRTX | 2,725 | $490.54 | $1.3M | View |
| Feb 27, 2026 | Sold | VRTX | 949 | $491.30 | $466K | View |
| Feb 27, 2026 | Sold | VRTX | 2,520 | $493.29 | $1.2M | View |
| Feb 27, 2026 | Sold | VRTX | 3,498 | $494.33 | $1.7M | View |
| Feb 27, 2026 | Sold | VRTX | 15,580 | $495.38 | $7.7M | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 2736 | Edward Meyercord PRESIDENT AND CEO, Extreme Networks. Morrisville, NC | $45.1M |
| 2737 | Raymond J. Lane Director, Hewlett Packard Enterprise. Spring, TX | $45.1M |
| 2738 | Robert H. Adcock Director, Home BancShares. Conway, AR | $45.1M |
| 2739 | Reshma Kewalramani CEO & President, Vertex Pharmaceuticals. Boston, MA | $45.1M |
| 2740 | Leigh Ann Pusey EVP, Corp. Affairs & Comm., Eli Lilly and. Indianapolis, IN | $45.1M |
| 2741 | Joshua E. Prime Director, Levi Strauss &. San Francisco, CA | $45.0M |
| 2742 | Holger Blankenstein EVP Airline, Controladora Vuela Compañía de Aviación, S.A.B. de C.V. | $45.0M |
Other Vertex Pharmaceuticals insiders
All VRTX insiders- Amit Sachdev$38.5MEVP Chief Patient & Ext Af Off. #3087 overall
- Stuart A. Arbuckle$33.1MEVP, COO. #3304 overall
- Ourania Tatsis$27.9MEVP, Chief Reg. & Quality Off.. #4003 overall
- Bruce I. Sachs$20.3MDirector. #5124 overall
- Jeffrey M. Leiden$18.3MExecutive Chairman. #4635 overall
- David Altshuler$18.0MEVP, Chief Scientific Officer. #5632 overall
Questions
How much stock does Reshma Kewalramani own?
Reshma Kewalramani holds $45,060,121 in listed stock based on SEC filings and current prices, mostly Vertex Pharmaceuticals (VRTX). That ranks 2739th on the Stock Rich List.
Is this Reshma Kewalramani's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Reshma Kewalramani last buy or sell stock?
The most recent open-market trade on file is a sale of 11,866 VRTX shares on Nov 6, 2026 at $531.53.